Intercept Cirrhosis Drug's Confirmatory Trial Could Face Design Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee weighing obeticholic acid's accelerated approval for primary biliary cirrhosis will also consider whether enrollment criteria or design changes in ongoing clinical outcomes study are needed to support full approval down the road.